The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 7.80
Ask: 8.20
Change: -0.15 (-1.84%)
Spread: 0.40 (5.128%)
Open: 8.15
High: 8.15
Low: 8.00
Prev. Close: 8.15
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Director

7 Jan 2020 07:00

RNS Number : 9112Y
Tekcapital plc
07 January 2020
 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

 

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

Board Addition

 

THE RT HON LORD WILLETTS FRS JOINS TEKCAPITAL'S BOARD

 

Tekcapital Plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, is pleased to announce that Lord David Willetts has joined the Board of Tekcapital with immediate effect.

 

The Rt Hon Lord Willetts FRS is President of the Resolution Foundation and former U.K. Minister for Universities and Science. He served as the Member of Parliament for Havant (1992-2015), and previously worked at HM Treasury and the No. 10 Policy Unit. Lord Willetts is a visiting Professor at King's College London, former Chair of the British Science Association and a member of the Council of the Institute for Fiscal Studies. He is also an Honorary Fellow of Nuffield College, Oxford. Lord Willetts has written widely on economic and social policy. His book 'The Pinch', which focused on intergenerational equity, was published in 2010, and he recently published 'A University Education'. Lord Willetts is a graduate of Oxford University and has been awarded numerous honorary doctorates.

 

Dr Clifford Gross, Executive Chairman at Tekcapital, commented: "We are very pleased to have Lord David Willetts join our board and believe that his extensive business and university experience, coupled with his knowledge regarding the commercialisation of scientific discoveries, will further enhance the board's skills and growth prospects for the Company."

 

The Rt Hon Lord Willetts said "Tekcapital is an exciting company with a global university network. I look forward to helping Tekcapital turn their ideas into the businesses of the future."

 

 

The following information regarding the appointment of Lord David Lindsay Willetts, aged 63, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 

Current directorships and/or partnerships:

Former directorships and/or partnerships (within the last five years):

 

8GT Advisory Limited

Biotech Growth Trust Plc

Booker Prize Foundation

Davco Limited

Eight Great Technologies Fund

Foundation for Science and Technology

Marchmount Executive Services Limited

Resolution Foundation

Sirius Constellation Limitied

Surrey Satellite Technology Ltd.

Thames Holdings Limited

UK Research and Innovation

Verditek Plc

Borough of Havant Sport and Leisure Trust

British Science Association

Genome Research Ltd and Sanger Institute

National Council for Universities and Business

Science Museum

The Biotech Industry Association

The Council For Industry and Higher Education

The Francis Crick Institute Limited

Vantix Diagnostics Inc.

 

 

Lord Willetts does not have any beneficial interest in the ordinary shares of the Company, but has been granted 100,000 stock options under the Company's stock option plan.

 

There are no further disclosures required under Schedule 2(g) of the AIM Rules for Companies.

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85

For further information, please contact:

Tekcapital Plc 

 

+1 305-200-3450

Clifford M. Gross, Ph.D. 

 

 

 

 

 

SP Angel  Corporate Finance LLP

(Nominated Adviser and Joint Broker)

 

+44 (0) 20 3470 0470 

Richard Morrison / Charlie Bouverat (Corporate Finance)

 

 

 

 

Novum Securities Limited (Joint Broker) 

 

 

 

+44 (0) 20 7399 9427

Colin Rowbury (Corporate Broking) 

 

 

 

Flagstaff Strategic and Investor Communications +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUPUCPGUPUGRQ
Date   Source Headline
22nd Aug 20227:00 amRNSNotification of Investor Webinar
18th Aug 20227:00 amRNSLucyd Portfolio Company Update
18th Aug 20227:00 amRNSInnovative Eyewear Inc. Closing of US $ 7.35 M IPO
15th Aug 20227:00 amRNSLucyd -Pricing of US$ 7.35 Million IPO
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jul 20227:00 amRNSHalf Year Report for period ending 31 May 2022
21st Jul 20224:40 pmRNSSecond Price Monitoring Extn
21st Jul 20224:35 pmRNSPrice Monitoring Extension
4th Jul 20224:41 pmRNSSecond Price Monitoring Extn
4th Jul 20224:35 pmRNSPrice Monitoring Extension
4th Jul 20227:00 amRNSSalarius First U.S.A. Bulk B2B Order
16th Jun 20229:55 amRNSGrant of Share Options
15th Jun 20222:42 pmRNSNotification of Major Holdings
7th Jun 20227:00 amRNSNotification of Major Holdings
1st Jun 20223:08 pmRNSNotification of Major Holdings
31st May 20222:30 pmRNSResult of AGM
30th May 20227:00 amRNSPortfolio Company Update :Salarius
25th May 20221:19 pmRNSTR-1: Notification of major holdings
25th May 20227:00 amRNSPlacing to Raise £2 Million (c.US$ 2.5M)
6th May 202211:36 amRNSNotice of AGM
6th May 20227:00 amRNSFinal Year End Record Results
5th May 20227:00 amRNSGuident Update
3rd May 20228:35 amRNSGuident Update
19th Apr 20227:00 amRNSPortfolio Company Update - Guident
1st Apr 20227:00 amRNSPortfolio Company Update - Salarius
25th Mar 202211:39 amRNSNotification of Major Holdings
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSSalarius Update
11th Feb 20225:58 pmRNSExercise of Stock Options and Total Voting Rights
11th Feb 20222:06 pmRNSSecond Price Monitoring Extn
11th Feb 20222:00 pmRNSPrice Monitoring Extension
11th Feb 202211:06 amRNSSecond Price Monitoring Extn
11th Feb 202211:01 amRNSPrice Monitoring Extension
4th Feb 20227:00 amRNSGuident Update
2nd Feb 20227:00 amRNSLucyd Expands Ecommerce Channels
4th Jan 20227:00 amRNSSalarius Completes Oversubscribed Crowdfund
29th Dec 20217:00 amRNSSalarius Appoints CEO
24th Dec 20217:00 amRNSSalarius Appoints Non Executive Director
14th Dec 20217:00 amRNSLucyd Filing for United States IPO
9th Dec 20217:00 amRNSSalarius Update
22nd Nov 202112:09 pmRNSHolding(s) in Company
16th Nov 20217:00 amRNSSalarius Update
15th Nov 20217:00 amRNSSalarius Update
11th Nov 20217:00 amRNSAppointment of new Auditor
4th Nov 20217:00 amRNSPortfolio Company Update: Lucyd Ltd ("Lucyd")
3rd Nov 20217:00 amRNSPlacing to raise £3.0 million
27th Oct 20217:00 amRNSSalarius Appointment of Chief Medical Officer
26th Oct 20214:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.